person

István N.

Country
Hungary
Department
Belgyogyaszati-Infektologiai Centrum Belgyogyaszati Osztaly

Research Overview

Data & Insights

medical_services
Primary Speciality
Main therapeutic area

handshake
Return Partnerships
Recurring site collaborations
140
Sites with multiple studies

Has run more than one trial at 140 of 233 partner sites.

Specializations

Liver Disease Management

This investigator specializes in the treatment of acute-on-chronic liver failure (ACLF), with particular focus on high-risk cases requiring hospital intervention. Their expertise extends to managing various grades of ACLF, particularly ACLF-1b, ACLF-2, and ACLF-3a conditions.

  • Advanced Liver Disease Complications
  • Hospital Mortality Risk Assessment
  • Cirrhosis Management

Their clinical interests include innovative therapeutic approaches for critical liver conditions.

Hepatic Complications

The investigator focuses on treating complex manifestations of liver disease, including hepatic encephalopathy and ascites. Their work addresses the challenges of metabolic dysfunction in liver failure, particularly concerning hyperammonemia.

  • Ascites Management
  • Behavioral and Physical Decline
  • Organ Dysfunction Assessment

Their expertise encompasses systemic inflammatory responses in liver disease progression.

Therapeutic Interventions

The investigator evaluates advanced treatment modalities for liver failure, including plasma exchange therapy and novel therapeutic approaches. Their work involves assessing treatment efficacy using specialized scoring systems like the CLIF-C ACLF score.

  • Standard Medical Treatment Optimization
  • Survival Rate Assessment
  • Innovative Treatment Protocols

They focus on developing comprehensive treatment strategies for complex liver conditions.

Related Investigators

Researchers in similar fields or departments

Want to know more about this investigator?

We can share extended profile information and contact details.

Is something out of date?

Tell us what needs correcting and we'll update this profile.